2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.08F.15 A Retrospective Study of Tislelizumab Combined with Chemotherapy in Patients with Locally Advanced Lung Cancer

EP.08F.15 A Retrospective Study of Tislelizumab Combined with Chemotherapy in Patients with Locally Advanced Lung Cancer

Back to course

Pdf Summary

This study evaluates the efficacy and safety of tislelizumab combined with chemotherapy as a treatment for patients with locally advanced lung cancer who are not initially considered suitable for radical resection. Conducted retrospectively, it involved data collection from patients who underwent at least two cycles of this combined therapy between October 2020 and November 2021.<br /><br />The study included 65 patients, categorized into different stages: 40.0% in stage A, 50.8% in stage B, and 9.2% in stage C. Patients underwent a median of three treatment cycles. Grade 3 adverse events were observed in 16.9% of the participants as per the Common Terminology Criteria for Adverse Events (CTCAE).<br /><br />Surgery was performed on 55 patients, resulting in an 84.6% surgical rate, with a median interval to surgery of 5.7 weeks. Of those, 45 patients (81.82%) underwent successful radical surgery via Video-Assisted Thoracoscopic Surgery (VATS), achieving a 100% R0 resection rate. Postoperative pathology confirmed tumor downstaging in 94.5% of the cases, with a pathological complete response (pCR) observed in 47.3% and a major pathological response (MPR) in 76.4% of the patients.<br /><br />The research concludes that the combination of tislelizumab with chemotherapy demonstrates substantial anti-tumor activity, reducing tumor volume and improving surgical resection rates. The treatment is also noted for its high pCR rate and acceptable safety profile. These findings suggest that this combination could be a promising strategy for downstaging and conversion therapy in locally advanced lung cancer, offering a potential new option for treatment.

Asset Subtitle

Jiarong Zhang

Meta Tag

Speaker Jiarong Zhang

Topic Local-Regional Non-small Cell Lung Cancer

Keywords

tislelizumab

chemotherapy

lung cancer

radical resection

Video-Assisted Thoracoscopic Surgery

tumor downstaging

pathological complete response

anti-tumor activity

conversion therapy

safety profile